Although health care has flatlined in the legislature for now, industry professionals continue discussing innovation in specialized forums. Orphan drug pricing has made its way into those discussions, signaling entities across the board are getting on the same page.
The Institute for Clinical and Economic Review (ICER) in a whitepaper released in May said value assessments of orphan and ultra-orphan medicines are far more challenging due to a number of obstacles, be it clinical or regulatory.
According to PharmExec.Com, ICER suggested in the whitepaper its willingness to accept input from groups which had in the past criticized its methodology. The organization signaled it was more open to consider the opinions of patients and manufacturers regarding price analysis and cost effectiveness.
“This is important because the media, some payers, and even some policymakers are looking to the organization, and others like it, to help determine good value for money in healthcare,” PharmExec.Com reports.
The nonprofit organization also has proposed adaptations to its existing value framework “to accommodate treatments for ultra-rare conditions,” according to PharmExec.Com. The public can comment on the proposals until the Sept. 25 deadline.